AAAAAA
Results: 1-25/34
Authors:
Burnett, AK
Citation: Ak. Burnett, Treatment of acute myeloid leukaemia in younger patients, BEST P R C, 14(1), 2001, pp. 95-118
Authors:
Burnett, AK
Citation: Ak. Burnett, Acute myeloid leukaemia - Preface, BEST P R C, 14(1), 2001, pp. VII-VII
Authors:
Burnett, AK
Citation: Ak. Burnett, Evaluating the contribution of allogeneic and autologous transplantation to the management of acute myeloid leukemia in adults, CANC CHEMOT, 48, 2001, pp. S53-S58
Authors:
Burnett, AK
Citation: Ak. Burnett, Introduction: Modern management of acute myeloid leukemia, SEM HEMATOL, 38(3), 2001, pp. 1-2
Authors:
Burnett, AK
Citation: Ak. Burnett, Gemtuzumab ozogamicin - Viewpoint, DRUGS, 61(9), 2001, pp. 1323-1324
Authors:
Yin, JAL
Wheatley, K
Rees, JKH
Burnett, AK
Citation: Jal. Yin et al., Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial, BR J HAEM, 113(3), 2001, pp. 713-726
Authors:
Langabeer, SE
Rogers, JR
Harrison, G
Wheatley, K
Walker, H
Bain, BJ
Burnett, AK
Goldstone, AH
Linch, DC
Grimwade, D
Citation: Se. Langabeer et al., EVI1 expression in acute myeloid leukaemia, BR J HAEM, 112(1), 2001, pp. 208-211
Authors:
Kottaridis, PD
Gale, RE
Frew, ME
Harrison, G
Langabeer, SE
Belton, AA
Walker, H
Wheatley, K
Bowen, DT
Burnett, AK
Goldstone, AH
Linch, DC
Citation: Pd. Kottaridis et al., The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogeneticrisk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials, BLOOD, 98(6), 2001, pp. 1752-1759
Authors:
Goldstone, AH
Burnett, AK
Wheatley, K
Smith, AG
Hutchinson, RM
Clark, RE
Citation: Ah. Goldstone et al., Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial, BLOOD, 98(5), 2001, pp. 1302-1311
Authors:
Grimwade, D
Walker, H
Harrison, G
Oliver, F
Chatters, S
Harrison, CJ
Wheatley, K
Burnett, AK
Goldstone, AH
Citation: D. Grimwade et al., The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial, BLOOD, 98(5), 2001, pp. 1312-1320
Authors:
Burnett, AK
Kell, J
Rowntree, C
Citation: Ak. Burnett et al., Acute myeloid leukemia: therapeutic indications, CURR OPIN H, 7(6), 2000, pp. 333-338
Authors:
Guinn, BA
Evely, RS
Walsh, V
Gilkes, AF
Burnett, AK
Mills, KI
Citation: Ba. Guinn et al., An in vivo and in vitro comparison of the effects of b2-a2 and b3-a2 p210BCR-ABL splice variants on murine 32D cells, LEUK LYMPH, 37(3-4), 2000, pp. 393-404
Authors:
Burnett, AK
Kell, J
Citation: Ak. Burnett et J. Kell, High dose cytarabine or transplantation for consolidation of younger patients with acute myeloid leukemia, CURR OPIN O, 12(2), 2000, pp. 110-115
Authors:
Burnett, AK
Kell, J
Rowntree, G
Citation: Ak. Burnett et al., Role of allogeneic and autologous hematopoietic stem cell transplantation in acute myeloid leukemia, INT J HEMAT, 72(3), 2000, pp. 280-284
Authors:
Baines, P
Fisher, J
Truran, L
Davies, E
Hallett, M
Hoy, T
Burnett, AK
Citation: P. Baines et al., The MEK inhibitor, PD98059, reduces survival but does not block acute myeloid leukemia blast maturation in vitro, EUR J HAEMA, 64(4), 2000, pp. 211-218
Authors:
Hofmann, WK
Kell, WJ
Fenaux, P
Castaigne, S
Ganser, A
Chomienne, C
Burnett, R
Kowal, C
Hoelzer, D
Burnett, AK
Citation: Wk. Hofmann et al., Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study, LEUKEMIA, 14(9), 2000, pp. 1583-1588
Authors:
McGlynn, AP
Padua, RA
Burnett, AK
Darley, RL
Citation: Ap. Mcglynn et al., Alternative effects of RAS and RAF oncogenes on the proliferation and apoptosis of factor-dependent FDC-P1 cells, LEUK RES, 24(1), 2000, pp. 47-54
Authors:
Lowenberg, B
Burnett, AK
Citation: B. Lowenberg et Ak. Burnett, Acute myeloid leukemia. Reply, N ENG J MED, 342(5), 2000, pp. 358-359
Authors:
Tennant, GB
Walsh, V
Truran, LN
Edwards, P
Mills, KI
Burnett, AK
Citation: Gb. Tennant et al., Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia, BR J HAEM, 111(3), 2000, pp. 853-862
Authors:
Tennant, GB
Truran, LN
Bailey-Wood, R
Burnett, AK
Citation: Gb. Tennant et al., Control of pH in human long-term bone marrow cultures with low-glucose medium containing zwitterion buffer lengthens the period of haemopoietic activity, BR J HAEM, 109(4), 2000, pp. 785-787
Authors:
Mills, KI
Walsh, V
Gilkes, AF
Sweeney, MC
Mirza, T
Woodgate, LJ
Brown, G
Burnett, AK
Citation: Ki. Mills et al., High FUS/TLS expression in acute myeloid leukaemia samples, BR J HAEM, 108(2), 2000, pp. 316-321
Authors:
Darley, RL
Burnett, AK
Citation: Rl. Darley et Ak. Burnett, Mutant RAS inhibits neutrophil but not macrophage differentiation and allows continued growth of neutrophil precursors, EXP HEMATOL, 27(11), 1999, pp. 1599-1608
Authors:
Burnett, AK
Citation: Ak. Burnett, Treatment of acute myeloid leukemia, N ENG J MED, 340(18), 1999, pp. 1438-1439
Authors:
Watson, M
Wheatley, K
Harrison, GA
Zittoun, R
Gray, RG
Goldstone, AH
Burnett, AK
Citation: M. Watson et al., Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone - Analysis of the MRC AML 10 trial, CANCER, 86(7), 1999, pp. 1231-1239
Authors:
Wheatley, K
Burnett, AK
Goldstone, AH
Gray, RG
Hann, IM
Harrison, CJ
Rees, JKH
Stevens, RF
Walker, H
Citation: K. Wheatley et al., A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial, BR J HAEM, 107(1), 1999, pp. 69-79